Genetic test may guide chemo choice for pancreatic cancer patients

NCT ID NCT07616362

Not yet recruiting Disease control Sponsor: Federation Francophone de Cancerologie Digestive Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tests whether a genetic signature can personalize chemotherapy for people with borderline resectable pancreatic cancer. About 110 participants will receive either a standard chemo regimen or one chosen based on their tumor's genetic profile. The goal is to see if personalized chemo improves event-free survival and increases the chance of successful surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: chemotherapy (nab-paclitaxel/gemcitabine or mFOLFIRINOX)
What this could lead to: If successful, this could show that using a genetic signature to choose chemotherapy improves survival and surgery rates for people with borderline resectable pancreatic cancer.
What could go wrong: This is a phase II trial with only 110 participants, so results are preliminary. The genetic test may not reliably predict which chemo works best, and both regimens have significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA

Contacts and locations

Locations

Hopital Nord Chu Saint Etienne

Saint-Priest-en-Jarez, France
Hôpital Beaujon

Clichy, France
Hôpital Lyon Sud

Pierre-Bénite, France
Hôpital Rangueil

Toulouse, France
Institut Paoli Calmettes

Marseille, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.